Last reviewed · How we verify
NCT04890873
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
Phase 1 trial testing ERX1000 in Obesity in 48 participants. Completed in 3 July 2023.
3 July 2023
Quick facts
| Lead sponsor | ERX Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 17 October 2019 |
| Primary completion | 3 July 2023 |
| Estimated completion | 3 July 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ERX1000 — full drug profile →
- Placebo
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
ERX Pharmaceuticals — full company profile →
Who can join
Adults 18 to 55, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, et al · · 2023 · cited 260× · PMID 36992862 · DOI 10.1016/j.eclinm.2023.101882 -
Signaling pathways in obesity: mechanisms and therapeutic interventions.
Wen X, Zhang B, Wu B, Xiao H, et al · · 2022 · cited 245× · PMID 36031641 · DOI 10.1038/s41392-022-01149-x -
The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside.
Shen X, Yang H, Yang Y, Zhu X, et al · · 2024 · cited 10× · PMID 39049964 · DOI 10.1002/mco2.664 -
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
Nicze M, Dec A, Borówka M, Krzyżak D, et al · · 2024 · cited 9× · PMID 39125772 · DOI 10.3390/ijms25158202
Verify or expand the search:
- PubMed search for NCT04890873
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04890873 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ERX Pharmaceuticals
- Last refreshed: 24 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04890873.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing